Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.

88 The interim OS analysis showed a trend toward favoring elacestrant in all patients (HR = 0.751) and those with ESR1-mut (HR = 0.592), with expectations for final OS reporting in 2022. 88 The most common treatment-related adverse events were nausea (25.3%), vomiting (11%), and fatigue (11%), primarily grade 1–2. 88 This is the fi

also in 53,322 other papers